Reliable Biopharmaceutical Expands Production Capacity at St. Louis, Missouri, Plant
02/16/2016
Lithium Dodecyl Sulfate and Sodium Dodecyl Sulfate are used in the manufacture of diagnostic tests and in the pharmaceutical industry for protein isolation and purification. Also known as Dodecyl Lithium Sulfate or Lithium Lauryl Sulfate, LDS and SDS are sold both in research and bulk containers.
Reliable Biopharmaceutical is an integrated developer and manufacturer of Active Pharmaceutical Ingredients (APIs) and High Purity Ingredients (HPIs) for pharmaceuticals and biologics.
“Reliable continues to leverage our quality systems and proprietary purification technology to produce the highest quality excipients in the world,” said David Feldker President/CEO. “We are committed to our customer’s success and their requirement for high purity ingredients.”
According to the firm, RB has established a strong position as a leading developer and manufacturer of complex generic injectable APIs. The company has a number of DMFs that have been accepted by Regulatory Agencies and has more in various stages of development. RB's products are the active ingredients for leading generic injectable drugs that treat cancer, heart disease, hypertension, anxiety and other serious and life threatening illnesses. RB also manufactures critical processing aids for the pharmaceutical industry and currently supplies these products to many of the world's leading pharmaceutical and biotechnology companies.
Project Announcements
Ashworth Bros. Upgrades Winchester, Virginia, Production Operations
11/15/2025
Feast & Fettle Plans Elkridge, Maryland, Production-Distribution Operations
11/15/2025
First Quality Retail Services Expands Mifflin County, Pennsylvania, Manufacturing Operations
11/15/2025
Meta Plans Beaver Dam, Wisconsin, Data Center Operations
11/15/2025
Modine Expands Buena Vista, Virginia, Operations
11/15/2025
Socomec Plans Suwanee, Georgia, Manufacturing Operations
11/15/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025